How should a new deep vein thrombosis (DVT) and pulmonary embolism (PE) be evaluated and managed in the outpatient setting?

Outpatient Management of New DVT and Pulmonary Embolism

For carefully selected low-risk patients with new DVT or PE, outpatient treatment is safe, cost-effective, and strongly recommended over hospitalization, provided appropriate support systems and follow-up are in place 1.

Risk Stratification for Outpatient Eligibility

Patient Selection Criteria

You must exclude patients with:

• Hemodynamic instability (shock, hypotension, or signs of right ventricular dysfunction)
• High-risk features: PESI class III-V or sPESI score >0
• Active major bleeding or severe thrombocytopenia (<50,000/mm³)
• Severe renal (CrCl <30 mL/min) or liver disease
• Significant comorbidities requiring hospitalization
• Previous VTE or known thrombophilic conditions
• Pregnancy
• Inability to comply with treatment or lack of adequate home support
• Inability to access timely follow-up care 2, 3, 1

Clinical Assessment

For suspected PE, use validated clinical probability scores (Wells criteria or Geneva score) combined with D-dimer testing 3, 4. Imaging should ideally occur within 24 hours for non-massive PE 5. For DVT, compression ultrasonography of proximal veins is the primary diagnostic modality 6.

Anticoagulation Regimen

First-Line Treatment Options

Direct oral anticoagulants (DOACs) are preferred as single-drug regimens 7, 1:

Option 1 (Preferred): Rivaroxaban 15 mg twice daily for 21 days, then 20 mg once daily 6, 7

Option 2: Apixaban (dosing per standard protocol) 7

Option 3: LMWH bridge followed by dabigatran or edoxaban 7

LMWH Dosing (if used)

• Enoxaparin: 1.5 mg/kg subcutaneously once daily for outpatient DVT/small PE 6
• For larger PE: Consider 1 mg/kg twice daily 6
• Dalteparin: 200 IU/kg once daily 6

LMWH is superior to unfractionated heparin for initial DVT treatment, particularly for reducing mortality and major bleeding 2, 8. Avoid LMWH if CrCl <30 mL/min 6.

Critical Outpatient Infrastructure Requirements

Immediate Discharge Requirements

You cannot discharge without:

1. Confirmed medication access - patient must be able to obtain anticoagulation immediately
2. Structured follow-up within 24-48 hours - either in-person or telephone review 7
3. 24/7 access point for patient questions or complications 7
4. Written and verbal instructions on bleeding signs, recurrence symptoms, and when to return 7

Follow-Up Protocol

• First week: At least one formal review (telephone or face-to-face) to assess compliance and complications 7
• Consultant review: Patients should be reviewed by a consultant (or designated senior clinician) prior to discharge on outpatient pathway 7
• Repeat assessment: For patients initially admitted with intermediate risk (PESI III), reassess with PESI/sPESI before early discharge; consider repeat RV function assessment if initially abnormal 7

Ancillary Measures

Compression Stockings

Begin compression stockings within 1 month of proximal DVT diagnosis and continue for minimum 1 year to prevent post-thrombotic syndrome 2.

Duration of Anticoagulation

• Provoked VTE (temporary risk factors): 3 months minimum 3, 5
• Unprovoked VTE: Consider extended treatment beyond 3-6 months, balancing recurrence risk against bleeding risk 3
• Cancer-associated VTE: Minimum 6 months, often indefinite 3

Common Pitfalls to Avoid

1. Don't discharge based on clinical judgment alone - always confirm absence of RV dysfunction if immediate discharge is planned, as catastrophic early death can occur if high-risk PE is misclassified 3

2. Don't use warfarin as initial monotherapy - requires LMWH bridge for minimum 5 days AND INR >2.0 for ≥24 hours 6

3. Don't assume all "low-risk" patients are suitable - the trials excluded many screened patients; strict inclusion criteria were used 2, 8

4. Don't forget HIT monitoring with UFH - check platelets every 2-3 days from day 4-14 if using unfractionated heparin (HIT risk up to 5%) 6

5. Don't discharge pregnant patients on DOACs or warfarin - these are contraindicated; use LMWH only and involve maternity services 7

Special Populations

Pregnancy/Postpartum

• Require consultant review and maternity service discussion before discharge 7
• PESI/sPESI scores not validated in pregnancy 7
• LMWH only - no DOACs or warfarin 7

Cancer Patients

• Consider factor Xa inhibitors (rivaroxaban, apixaban) as alternative to LMWH 9
• Exception: gastrointestinal/urothelial cancers or significant drug-drug interactions - prefer LMWH 9

Obesity (up to 150 kg)

Standard doses of rivaroxaban and apixaban are appropriate 9